How much cash does Solid Biosciences Inc. generate?

Solid Biosciences Inc. (SLDB) generated -$171.7M in operating cash flow over the trailing twelve months.

What is Solid Biosciences Inc.'s free cash flow?

After $1.2M of capital expenditures, Solid Biosciences Inc.'s free cash flow was -$172.9M over the trailing twelve months, down 61.1% year over year.

Where does Solid Biosciences Inc.'s cash flow data come from?

Every line is extracted from Solid Biosciences Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Solid Biosciences Inc. SLDB Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Net income	-$174.33M-39.8%	-$124.7M-29.9%	-$96.02M-11.7%	-$85.98M-19.1%
Depreciation and amortization	$1.64M-33.4%	$2.46M-4.9%	$2.58M+7.2%	$2.41M-18.8%
Stock-based compensation	$16.91M+60.8%	$10.52M+38.0%	$7.63M+1.2%	$7.54M-43.6%
Change in accounts payable	-$1.09M-150%	$2.21M—	——	-$5.25M-534%
Change in accrued liabilities	$4.05M-15.0%	$4.77M—	——	——
Change in other assets	——	——	——	-$3.7M-140%
Other working capital changes	$239K+172%	$88K+124%	-$374K—	——
Change in operating lease liabilities	-$1.79M-6.6%	-$1.68M—	——	——
Net cash from operating activities	-$156.29M-56.3%	-$100.01M-6.2%	-$94.18M+3.9%	-$97.98M-26.0%
Capital expenditures	$1.15M+76.3%	$654K-56.8%	$1.52M-49.8%	$3.02M+135%
Purchases of investments	$235.89M+15.4%	$204.34M—	——	$182.76M—
Net cash from investing activities	——	——	$9.69M-83.6%	$59.16M—
Repayments of debt	$723K+52.9%	$473K—	——	——
Proceeds from issuance of common stock	——	$457K—	——	$72.55M—
Net cash from financing activities	$196.05M+60.1%	$122.44M—	——	$74.83M-44.7%
Net increase (decrease) in cash	-$20.3M—	——	——	$36.01M—
Interest paid	——	——	——	——
Accretion (Amortization) of Discounts and Premiums, Investments	$1.87M-47.8%	$3.59M+49.2%	$2.41M—	——
Change In Fair Value Of Derivative Liabilities	-$6.05M-227%	$4.75M—	$0—	——
Common Stock Issued As Up Front Payment For Collaboration And License Agreement	$0-100%	$2M—	$0—	——
Accrued expenses and other liabilities	$4.05M-15.0%	$4.77M—	——	——
Operating lease liabilities	-$1.79M-6.6%	-$1.68M—	——	——
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	——	-$3.7M-140%
Non Cash Lease Expense	$2.37M-0.8%	$2.39M—	——	——
Other Noncash Income (Expense)	$239K+172%	$88K+124%	-$374K—	——
Payments For Proceeds From Availableforsale Securities Shortterm	-$178.5M+5.5%	-$188.9M-46.9%	-$128.63M+39.6%	-$212.81M—
Payments Of Common Stock And Pre Funded Warrants Issuance Costs In Public Offering	——	$0—	——	——
Payments Of Stock Issuance Costs	$0—	——	——	——
Proceeds From Issuance Of Common Stock And Pre Funded Warrants In Public Offering Net Of Underwriting Discounts And Commissions	——	$0—	——	——
Proceeds From Issuance Of Common Stock And Pre Funded Warrants In Private Placement	——	——	——	——
Proceeds From Issuance Of Common Stock In At The Market Public Offering Net Of Sales Commissions	——	——	——	——
Repayment of Long-Term Debt, Long-Term Lease Obligation, and Capital Security	$723K+52.9%	$473K—	——	——
Accrued payables for capital expenditures	——	$0—	——	——
Common Stock Issued As Payment For Developmental Milestone Consideration	——	$0—	——	——
Increase Decrease In Operating Lease Liability	-$1.79M-6.6%	-$1.68M—	——	——
Increase Decrease In Right Of Use Asset And Lease Liability Due To Lease Termination	$0+100%	-$261K-3.6%	-$252K+45.7%	-$464K+62.4%
Operating Lease Payments	$4.18M-2.1%	$4.26M-5.3%	$4.5M—	——
Leased assets obtained in exchange for operating lease liabilities	$0—	——	$121K-99.6%	$29.13M+9,295%
Operating cash flows from finance leases	$91K-80.6%	$469K+25.1%	$375K—	——
Financing Cash Flows For Finance Leases Principal Portion Of Finance Lease Payment	$723K+113%	$340K—	——	——
Free cash flow	-$157.44M-56.4%	-$100.67M-5.2%	-$95.7M+5.2%	-$100.99M-27.8%
Free cash flow	-$157.44M-56.4%	-$100.67M-5.2%	-$95.7M+5.2%	-$100.99M-27.8%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Solid Biosciences Inc..

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

How much cash does Solid Biosciences Inc. generate?: Solid Biosciences Inc. (SLDB) generated -$171.7M in operating cash flow over the trailing twelve months.
What is Solid Biosciences Inc.'s free cash flow?: After $1.2M of capital expenditures, Solid Biosciences Inc.'s free cash flow was -$172.9M over the trailing twelve months, down 61.1% year over year.
Where does Solid Biosciences Inc.'s cash flow data come from?: Every line is extracted from Solid Biosciences Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.